WO2002098457A3 - Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses - Google Patents

Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses Download PDF

Info

Publication number
WO2002098457A3
WO2002098457A3 PCT/US2002/000295 US0200295W WO02098457A3 WO 2002098457 A3 WO2002098457 A3 WO 2002098457A3 US 0200295 W US0200295 W US 0200295W WO 02098457 A3 WO02098457 A3 WO 02098457A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
recombinant
viral
expressing
protein
Prior art date
Application number
PCT/US2002/000295
Other languages
French (fr)
Other versions
WO2002098457A2 (en
Inventor
Matthias J Schnell
Roger J Pomerantz
Original Assignee
Univ Jefferson
Matthias J Schnell
Roger J Pomerantz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson, Matthias J Schnell, Roger J Pomerantz filed Critical Univ Jefferson
Publication of WO2002098457A2 publication Critical patent/WO2002098457A2/en
Publication of WO2002098457A3 publication Critical patent/WO2002098457A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention provides recombinant, replication-competent Rhabdovirus vaccine strain-based expression vectors for expressing heterologous viral antigenic polypeptides such as immunodeficiency virus envelope proteins or subparts thereof. An additional transcription stop/start unit within the Rhabdovirus genome is inserted to express the heterologouos antigenic polypeptides. The HIV-1 gp 160 protein is stably and functionally expressed, as indicated by fusion of human T cell-lines after infection with the recombinant RVs. Inoculation of mice with the recombinant Rabies viruses expressing HIV-1 gp160 induces a strong humoral response directed against the HIV-1 envelope protein after a single boost with an isolated recombinant HIV-1 gp120 protein. Moreover, high neutralization titers, Up to 1:800, against HIV-1 are detected in the mouse sera. The present invention also shows that a single vaccination with recombinant RV expressing HIV-1 envelope protein elicits a strong, long-lasting CTL response specific against HIV-1 proteins, such as the envelope protein of different HIV-1 strains. These recombinant viral vectors expressing viral antigenic polypeptides provide useful and effective pharmaceutical compositions for the generation of viral specific immune responses.
PCT/US2002/000295 2001-01-17 2002-01-08 Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses WO2002098457A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76131201A 2001-01-17 2001-01-17
US09/761,312 2001-01-17

Publications (2)

Publication Number Publication Date
WO2002098457A2 WO2002098457A2 (en) 2002-12-12
WO2002098457A3 true WO2002098457A3 (en) 2003-04-24

Family

ID=25061854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000295 WO2002098457A2 (en) 2001-01-17 2002-01-08 Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses

Country Status (1)

Country Link
WO (1) WO2002098457A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8486420B2 (en) 2005-02-15 2013-07-16 The University Of North Carolina At Chapel Hill Live virus vaccines

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440219A1 (en) * 1990-02-02 1991-08-07 SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN cDNA corresponding to the genome of negative-strand RNA viruses, and process for the production of infectious negative-strand RNA viruses
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
WO1994008022A1 (en) * 1992-09-28 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Vector to deliver and express foreign gene
EP0702085A1 (en) * 1994-07-18 1996-03-20 Akzo Nobel N.V. Recombinant infectious non-segmented negative strand RNA virus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
EP0440219A1 (en) * 1990-02-02 1991-08-07 SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN cDNA corresponding to the genome of negative-strand RNA viruses, and process for the production of infectious negative-strand RNA viruses
WO1994008022A1 (en) * 1992-09-28 1994-04-14 Commonwealth Scientific And Industrial Research Organisation Vector to deliver and express foreign gene
EP0702085A1 (en) * 1994-07-18 1996-03-20 Akzo Nobel N.V. Recombinant infectious non-segmented negative strand RNA virus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CONZELMANN K K: "NONSEGMENTED NEGATIVE-STRAND RNA VIRUSES: GENETICS AND MANIPULATION OF VIRAL GENOMES", ANNUAL REVIEW OF GENETICS, ANNUAL REVIEWS INC., PALO ALTO, CA, US, vol. 32, no. 32, 1998, pages 123 - 162, XP008005872, ISSN: 0066-4197 *
CONZELMANN K-K ET AL: "RESCUE OF SYNTHETIC GENOMIC RNA ANALOGS OF RABIES VIRUS BY PLASMID-ENCODED PROTEINS", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 68, no. 2, February 1994 (1994-02-01), pages 713 - 719, XP001034147, ISSN: 0022-538X *
CONZELMANN K-K: "GENETIC MANIPULATION OF NON-SEGMENTED NEGATIVE-STRAND RNA VIRUSES", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 77, 1996, pages 381 - 389, XP002911692, ISSN: 0022-1317 *
LUYTJES W ET AL: "AMPLIFICATION, EXPRESSION, AND PACKAGING OF A FOREIGN GENE BY INFLUENZA VIRUS", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 59, no. 6, 22 December 1989 (1989-12-22), pages 1107 - 1113, XP000083570, ISSN: 0092-8674 *
PATTNAIK A K ET AL: "REPLICATION AND AMPLIFICATION OF DEFECTIVE INTERFERING PARTICLE RNAS OF VESICULAR STOMATITIS VIRUS IN CELLS EXPRESSING VIRAL PROTEINS FROM VECTORS CONTAINING CLONED CDNAS", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 64, no. 6, June 1990 (1990-06-01), pages 2948 - 2957, XP001069625, ISSN: 0022-538X *
SCHNELL M J ET AL: "INFECTIOUS RABIES VIRUSES FROM CLONED CDNA", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 13, no. 18, 1 September 1994 (1994-09-01), pages 4195 - 4203, XP000612065, ISSN: 0261-4189 *

Also Published As

Publication number Publication date
WO2002098457A2 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
Kardani et al. Prime-boost vaccine strategy against viral infections: Mechanisms and benefits
Naskalska et al. Virus like particles as immunogens and universal nanocarriers
Doan et al. Virus‐like particles as HIV‐1 vaccines
Pinto et al. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers
Hanke et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime
Ludwig et al. Virus-like particles—universal molecular toolboxes
Haynes et al. Particle-mediated nucleic acid immunization
WO2001091536A3 (en) Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens
WO2008026225A3 (en) A vaccine for chikungunya virus infection
WO1996030523A2 (en) Antigen presentation system based on retrovirus-like particles
WO2001060847A3 (en) avirulent, immunogenic flavivirus chimeras
WO2002022686A3 (en) Defensin-antigen fusion proteins
US20110142880A1 (en) Lentivirus-based immunogenic vectors
US9944935B2 (en) Methods to improve vector expression and genetic stability
Layton et al. Induction of single and dual cytotoxic T‐lymphocyte responses to viral proteins in mice using recombinant hybrid Ty–virus‐like particles
Lu Combination DNA plus protein HIV vaccines
EP2356133B1 (en) Recombinant protein bodies as immunogen-specific adjuvants
WO2001055330A3 (en) Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses
WO2002022687A3 (en) Viral chemokine-tumur antigen fusion proteins
Hinkula et al. A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations
WO2002089728A3 (en) Recombinant rhabdoviruses as live-viral vaccines
Mehdi Sadat et al. Application of SCR priming VLP boosting as a novel vaccination strategy against HIV-1
Wang et al. Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming
WO2002098457A3 (en) Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses
Koopman et al. Comparison of intranasal with targeted lymph node immunization using PR8‐Flu ISCOM adjuvanted HIV antigens in macaques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP